EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Platinum-based chemotherapy was the standard for lung cancer.
• Epidermal growth factor receptor (EGFR) mutations ushered in targeted therapies for non-small-cell lung cancer (NSCLC).
• EGFR tyrosine kinase inhibitors (TKIs) are preferred for advanced NSCLC with common EGFR mutations due to superior efficacy.

Purpose of the Study:

• To systematically review clinical research on EGFR exon 20 insertion (ex20ins) mutations in NSCLC.
• To summarize the latest data on emerging therapies for EGFR ex20ins mutations.
• To discuss future prospects and treatments for NSCLC patients with EGFR ex20ins mutations.

Main Methods:

• Systematic review of recent clinical research.
• Summary of current treatment data.
• Discussion of emerging therapies and future directions.

Main Results:

• EGFR ex20ins mutations confer resistance to standard EGFR-TKIs.
• Patients with EGFR ex20ins mutations have a poor prognosis.
• New drugs targeting EGFR ex20ins mutations have been approved, offering new hope.

Conclusions:

• EGFR ex20ins mutations represent a distinct subset of NSCLC with unique therapeutic challenges.
• Emerging therapies show promise for improving outcomes in this patient population.
• Continued research is crucial for optimizing treatment strategies for EGFR ex20ins NSCLC.